Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOAd703 with Chemotherapy in Advanced Solid Tumors
NCT03225989Phase 2Completed
- Sponsor
- Lokon Pharma
- Start
- Mar 2018
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of delolimogene mupadenorepvec in pancreatic adenocarcinoma (PDAC), cholangiocarcinoma, colorectal cancer (CRC), ovarian cancer, sponsored by Lokon Pharma. Started Mar 2018; status: completed.
02
Drugs
delolimogene mupadenorepvec
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinomacolorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT03225989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225989.